Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127737191 | 12773719 | 1 | I | 20160612 | 20160923 | 20160923 | PER | US-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023374 | GLENMARK | DHILLON S. KARAM S. JACKS S. EL FEGHALY R.. RARE PRIMARY CUTANEOUS ASPERGILLOSIS IN CRITICALLY ILL NEONATE. 74TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2016;74 (5 SUPPL. 1):PP AB216 | 0.00 | N | M | Y | 0.00000 | 20160923 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127737191 | 12773719 | 1 | SS | FLUCONAZOLE. | FLUCONAZOLE | 1 | Unknown | U | 0 | ||||||||||
| 127737191 | 12773719 | 2 | PS | VORICONAZOLE. | VORICONAZOLE | 1 | Unknown | U | 203503 | ||||||||||
| 127737191 | 12773719 | 3 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | U | 203503 | |||||||||||
| 127737191 | 12773719 | 4 | C | ACYCLOVIR /00587301/ | ACYCLOVIR | 1 | Unknown | U | 0 | ||||||||||
| 127737191 | 12773719 | 5 | C | AMPHOTERICIN B. | AMPHOTERICIN B | 1 | Unknown | 5 MG/KG, QD | U | 0 | 5 | MG/KG | |||||||
| 127737191 | 12773719 | 6 | C | AMPHOTERICIN B. | AMPHOTERICIN B | 1 | U | 0 | |||||||||||
| 127737191 | 12773719 | 7 | C | NYSTATIN. | NYSTATIN | 1 | Topical | UNK | U | 0 | |||||||||
| 127737191 | 12773719 | 8 | C | NYSTATIN. | NYSTATIN | 1 | U | 0 | |||||||||||
| 127737191 | 12773719 | 9 | C | MICAFUNGIN | MICAFUNGIN | 1 | Unknown | UNK | U | 0 | |||||||||
| 127737191 | 12773719 | 10 | C | MICAFUNGIN | MICAFUNGIN | 1 | U | 0 | |||||||||||
| 127737191 | 12773719 | 11 | C | ANTIBIOTICS | UNSPECIFIED INGREDIENT | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127737191 | 12773719 | 1 | Aspergillus infection |
| 127737191 | 12773719 | 2 | Aspergillus infection |
| 127737191 | 12773719 | 3 | Candida infection |
| 127737191 | 12773719 | 4 | Aspergillus infection |
| 127737191 | 12773719 | 5 | Aspergillus infection |
| 127737191 | 12773719 | 6 | Candida infection |
| 127737191 | 12773719 | 7 | Aspergillus infection |
| 127737191 | 12773719 | 8 | Candida infection |
| 127737191 | 12773719 | 9 | Aspergillus infection |
| 127737191 | 12773719 | 10 | Candida infection |
| 127737191 | 12773719 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127737191 | 12773719 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127737191 | 12773719 | Drug ineffective | |
| 127737191 | 12773719 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |